品质为先。

     

APAC MARKETS

我们设法促进高度专业化和具有科学价值的领域的发展,以提高医疗保健的标准。

发现更多关于美纳里尼集团的信息

30 多年来,美纳里尼一直致力于推动研发,为受严重健康问题影响的患者提供创新且有效的药物和医疗保健解决方案。

在13个主要市场获取进入亚太地区所有主要市场的单点式入口。

分享您的合作意向

充分利用我们的全渠道方法使您的品牌在亚太地区增长。

MARKETS

亚太地区的医疗行业正在快速增长。美纳里尼亚太隶属于世界领先的意大利生物制药公司,在该地区13个主要市场拥有强大的布局。

作为众多全球医疗保健公司的首选合作伙伴,我们参与整个药品开发生命周期,挖掘增长机会并扩大其品牌影响力。在此过程中,我们还为医务工作者和患者提供优质医疗产品和技术支持,以提高标准并为未来缔造健康生活。

我们的亚太地区总部

A. MENARINI ASIA-PACIFIC HOLDINGS PTE LTD
A. MENARINI ASIA-PACIFIC PRIVATE LIMITED
A. MENARINI SINGAPORE PTE LTD
A. MENARINI BIOMARKERS SINGAPORE PTE LTD

30 Pasir Panjang Road,
Mapletree Business City,
#08-32 Singapore 117440
Tel: +65-6494-7200
Fax: +65-6999-1787

 

2021

2021

  • 2021 - 12 - 23

    Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe and Other Key Global Territories

    Menarini Group Obtains Exclusive Rights to Commercialize NEXPOVIO for the Treatment of Hematologic and Solid Tumor Oncology Indications in Europe (including the United Kingdom), Latin America and Other Key Countries Karyopharm to Receive $75 Million Upfront, then Eligible to Receive Up to $202.5 Million in Future Milestones, Plus Tiered, Double-digit Royalties on Net Sales
  • 2021 - 11 - 04

    Menarini Receives FDA Orphan Drug Designation for SEL24/MEN1703, a first in class, dual PIM/FLT3 inhibitor for the Treatment of Acute Myeloid Leukemia

    Florence (Italy) November 4th, 2021 – The Menarini Group announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) to SEL24/MEN1703 for the treatment of Acute Myeloid Leukemia (AML). SEL24/MEN1703 is a first-in-class, orally available, dual PIM/FLT3 inhibitor, in-licensed by Menarini from Ryvu Therapeutics, and currently investigated in the DIAMOND-01 trial as a single agent for the treatment of patients with relapsed/refractory AML.
  • 2021 - 10 - 20

    Menarini Group and Radius Health Announce Positive Phase 3 Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer

    Florence, Italy and Boston, Mass., October 20, 2021 – the Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) today announced positive topline results from the EMERALD study. The study was designed to evaluate elacestrant as a monotherapy versus the standard of care (SoC) for the treatment of ER+/HER2- advanced or metastatic breast cancer (mBC). There were two primary endpoints: progression-free survival (PFS) in the overall population and PFS in patients with tumors harboring Estrogen Receptor 1 (ESR1) mutations.
  • 2021 - 08 - 22

    Menarini Enters into an Exclusive Licensing Agreement with Daiichi Sankyo to Commercialise TARLIGE® in Singapore, Malaysia, and the Philippines

    Singapore, 23 August, 2021 - A. Menarini Asia-Pacific Holdings Pte. Ltd., part of the leading Italian global biopharmaceutical company Menarini Group, signed a multi-year exclusive licensing agreement to assume the registration, sales, marketing, and distribution of the orally administered gabapentinoid, mirogabalin (brand name; TARLIGE®), in the Philippines, Malaysia and Singapore.
  • 2021 - 07 - 21

    美纳里尼亚太公司收购礼来公司希爱力®Cialis®品牌(他达拉非) 增强美纳里尼中国男性健康产品线

    新加坡2021年7月22日 /美通社/ -- 作为全球规模最大的意大利生物制药公司之一,美纳里尼集团(Menarini Group)旗下美纳里尼亚太公司(A. Menarini Asia-Pacific Holdings Pte Ltd)今天宣布在中国完成对礼来公司(Eli Lilly and Company)Cialis®(希爱力®)品牌的收购。通过此次收购,美纳里尼将接管该品牌的所有权,并负责其所有销售、市场推广和分销工作。
  • 2021 - 04 - 08

    Menarini Pills of Art Junior project launched, video clips made by the younger generations for children and teenagers

    Florence, Italy, 9th April 2021. “Who are the people depicted in the Primavera and why are they dancing in an orchard instead of a ballroom? “or “ Why was the Medusa painted on a shield?” These are just some of the questions posed by the young protagonists of the Pills of Art Junior series, now online in Italian and English on the Menarini Group YouTube channel, aimed at getting the younger generations interested in some of the world’s timeless masterpieces. These short videoclips reveal anecdotes, details and unprecedented curiosities on some of the most famous works of art, mainly from the Italian Renaissance period, thanks to simple and straightforward questions put by children and teenagers to the (almost) equally young art experts.